Sonnet BioTherapeutics (NASDAQ:SONN – Get Free Report) announced its quarterly earnings results on Thursday. The company reported ($1.56) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($11.12) by $9.56, Zacks reports.
Sonnet BioTherapeutics Trading Down 1.3 %
Shares of NASDAQ:SONN opened at $1.54 on Friday. The firm’s 50 day moving average price is $1.65 and its 200-day moving average price is $2.24. Sonnet BioTherapeutics has a twelve month low of $1.41 and a twelve month high of $18.72.
Wall Street Analysts Forecast Growth
Separately, Chardan Capital dropped their price target on shares of Sonnet BioTherapeutics from $30.00 to $20.00 and set a “buy” rating on the stock in a report on Friday, December 20th.
About Sonnet BioTherapeutics
Sonnet BioTherapeutics Holdings, Inc, a biotechnology company, owns a platform for biologic medicines of single or bifunctional action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues.
Featured Articles
- Five stocks we like better than Sonnet BioTherapeutics
- ESG Stocks, What Investors Should Know
- Watch These 3 Stocks—High Short Interest and Big Upside Potential
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Cisco Roars Back: Is the Tech Giant Reborn?
- How to Invest in the Best Canadian Stocks
- Albemarle’s Earnings Are In—Is the Stock a Buy Now?
Receive News & Ratings for Sonnet BioTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sonnet BioTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
